GENE:LSE:LSE-UBS (Irl) ETF Public Limited Company - Global Gender Equality UCITS ETF (GBX)

ETF | Others |

Last Closing

USD 1681.9

Change

+3.90 (+0.23)%

Market Cap

N/A

Volume

2.13K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+4.67 (+3.61%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.03 (+0.15%)

USD 588.35B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.32%)

USD 588.35B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.70 (+1.10%)

USD 266.08B
0QZO:LSE 0QZO

-1.90 (-1.71%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.07 (+0.22%)

USD 244.75B
0QZ3:LSE Qualcomm Inc.

+1.16 (+0.69%)

USD 202.26B
0R24:LSE Intel Corp.

+0.63 (+3.28%)

USD 196.14B

ETFs Containing GENE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.00% 68% D+ 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.00% 68% D+ 64% D
Trailing 12 Months  
Capital Gain 16.15% 68% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.15% 67% D+ 66% D+
Trailing 5 Years  
Capital Gain 59.26% 74% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.26% 71% C- 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 19.62% 85% B 84% B
Dividend Return 19.62% 85% B 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 192.41% 12% F 10% F
Risk Adjusted Return 10.20% 29% F 41% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.